| abstract |
An indole-derived compound of general formula (1) wherein: R1 is -S (O) 0-2-A, -C (O) -A, or - (CH2) 0-1-A, where A is selects from aryl and heteroaryl, optionally substituted with one or more groups selected from hydroxyl, cyano, lower alkyl, lower alkoxy, thioalkyl, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, alkylcarbonyl, alkylsulfonyl, haloalkylsulfonyl, amino, alkylamino, dialkylamino, alkylaminocarbonylamino , alkylcarbonylamino, alkylaminosulfonyl, and alkylsulfonylamino; R 2 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, and C 1-6 thioalkyl; R3 is selected from hydrogen and C1-6 alkyl; R4 is selected from hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 thioalkyl, haloalkyl, cyano, and alkylcarbonyl; and one of R5, R6 or R7 is a group of general formula (2), wherein W is a -CH- group or a nitrogen atom; and R8, R9 and R10 are each independently selected from hydrogen and C1-10 alkyl; or R8 and R9 together form a C3-4 alkylene; and the others are independently selected from hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 thioalkyl, haloalkyl, cyano, and alkylcarbonyl. Or individual isomers, racemic or non-racemic mixtures of isomers, pro-drugs, or pharmaceutically acceptable salts or solvates thereof. Its use for the preparation of medicines, processes to prepare it and pharmaceutical composition that includes it. The compound of formula (1) is useful for the treatment or prevention of a disease that improves with 5-HT6 agonists in particular for a disease comprising CNS disorders such as for example psychosis, schizophrenia, manic depressions, neurological disorders, disorders of memory, attention deficit syndrome, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease; disorders of the gastrointestinal tract; and obesity |